处方,提供和获得治疗勃起功能障碍的药物:公共卫生中的悖论?
André Luiz de Godoi1, Fernando Nestor Facio Junior1
1Departamento de Urologia, Faculdade de Medicina de São José do Rio Preto. Av. Brig. Faria Lima 5416, São José do Rio Preto. 15090-000 São Paulo Brasil. andregodoi.farmacia@gmail.com.
国家全面关注男性健康政策 (PNAISH) 没有将勃起功能障碍 (ED) 的药物纳入SUS,尽管它的目标是. 这种政策差距影响患者在公共卫生保健中获得必要的ED治疗.
科学领域:
- 公共卫生 公共卫生
- 男人的健康 男人的健康
- 卫生政策 卫生政策
背景情况:
- 全国全面关注男性健康政策 (PNAISH) 旨在改善男性健康,但未将勃起功能障碍 (ED) 药物纳入SUS.
- 经过13年,在公共卫生系统 (SUS) 中获得ED治疗仍然是一个挑战.
研究的目的:
- 思考PNAISH目标与苏联境内缺乏获得ED药物的冲突.
- 分析这一政策缺口对男性健康门诊服务中的患者护理的影响.
主要方法:
- 一个高度复杂的医院的男性健康门诊服务的临床观察的基于意见的反思.
- 分析现有的医疗保健政策和法规,包括2015年改名和圣保罗的SS-83决议.
主要成果:
- 治疗勃起障碍的药物没有纳入SUS药物援助协议.
- 司法化是获得非协议药物的机制,对处方治疗有潜在的机构资金.
结论:
- 在PNAISH的总体目标和ED治疗在SUS中的实际纳入之间存在很大的差距.
- 医疗机构可以在由附属医生处方时资助SUS协议所不涵盖的药物,这突显了对司法程序的依赖.
更多相关视频
12:21Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections
Published on: October 31, 2017
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Control Governance: Regulatory Bodies and Their Impact
